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Abstract: Growth Hormone (GH) may have many more effects on the human body 
than those commonly known by the public. A study was conducted to determine 
what these additional functions may be, if these functions could necessitate the 
continued use of GH treatment for adults with Growth Hormone Deficiency (GHD), 
and how these effects might invite the additional usage of GH as a treatment for 
normal individuals. Research consisted of a literature review and a statistical 
analysis of 86 adult GHD reports regarding how GH treatment had affected various 
symptoms. Reports were analyzed for significance using one-way ANOVAs. 
Observed results support that GH impacts energy, cognition, the cardiovascular 
system, the integumentary system, thermoregulation, wound regeneration, and the 
immune system. Each of these observed effects support that GH treatment may be 
a requirement to maintain the health of adult GHD patients. Literature review results 
also support that GH could be a possible treatment for cognitive impairment and 
nervous tissue injury in normal individuals. Results also suggest that GH treatment 
may not adequately attenuate hypohidrosis or poor thermoregulation symptoms in 
GHD patients.  
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Introduction: 
Growth Hormone (GH) is an important hormone produced and secreted from 
the pituitary gland. As its name suggests, it is most known for its role in the 
elongation of bones from infancy until adulthood. GH is often prescribed to children 
to treat known and idiopathic conditions that inhibit growth rates. The insistence on 
this titular role being the only important mechanism caused by GH secretion has 
been a majorly debated topic. Until the early aughts, most patients with GH 
deficiency (GHD) stopped receiving treatment when they were fully grown. It had 
been thought that there was no furthered need for the hormone supplementation as 
again the titular role was thought to be the only role, and secretions of GH in healthy 
adults were observed to decrease substantially. Hypersecretion of GH was also 
observed to be detrimental to the body. In tandem, it had appeared that GH 
treatment cessation for adults with GHD was the correct choice until these patients 
were studied over an extended period.  
The shared symptoms of these patients invited furthered research on GH. As 
a hormone this molecule is secreted into the blood stream. It therefore is able to reach 
the surface of most human cells. Most cells of the body also have receptors for growth 
hormone (McKinley 674). These factors support that growth hormone could have 
many more important functions in the body. The following thesis studies the health 
and symptoms of 86 adult GHD patients and reviews the recent findings concerning 
these many possible GH functions. The primary focus was to evaluate the continued 
use of GH treatment for adult GHD patients and the possible use of GH to treat a 
number of other diseases. 
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Materials and Methods:  
Literature collected for this study was found using the databases Proquest, 
Science Direct, Elsevier, Clinical Skills, and Access Medicine. Gardner-Webb’s library 
database includes these databases in its search, so it was prominently used. Standard 
up to date undergraduate anatomy and cell biology textbooks were also used. All 
articles obtained were in a digital format. The author of this review read and annotated 
each article to truly understand the information held within each. 
A survey was also conducted to evaluate whether patients’ symptoms align 
with these recent literature findings. The survey follows current guidelines set by the 
American Psychological Association concerning the ethical treatment of humans. CITI 
training to conduct social and behavioral research was attained along with exempt 
IRB research approval prior (i.e. file number 18100301) to the uploading of the survey. 
The survey itself was created using the webtool Google Forms. It includes an informed 
consent document to be read by participants before they begin the survey. A 
debriefing statement is also included at the end of the survey for participants to read. 
The survey was posted on the Magic Foundation Adult GHD and Panhypopituitarism 
Facebook group. Members were invited to take the survey, but they could also scroll 
past the post if they did not wish to participate. Subjects were only at minimal risk. 
This is estimated based on the fact that individuals answered questions anonymously. 
Each subject attained a random number before survey was taken. This was 
accomplished by them clicking a link that redirects them to a random number 
generator and then them pasting the resulting number to their second survey question. 
No identifying factors were collected. Thus, not even the individual conducting the 
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study was able to identify any of the participants. The study was also conducted online 
which mitigates breaches of confidentiality by other subjects. Subjects were also 
asked to skip questions they found to be too personal. This was to reduce any 
emotional risks that may have arisen when someone took the survey. There are only 
two questions that must be answered in the survey. The first asks participants to 
confirm that they are 18 or older, have used GH treatment, have read the informed 
consent document, and are aware that they can ask questions or drop out (i.e. by 
emailing the researchers with their random number) at any time. The second forces 
participants to copy/paste the previously mentioned random number. The remaining 
questions concern the possible effects of GH and the demographics of the 
participants. Questions are worded in a manner that does not lead individuals to select 
specific answers. Results of the previously mentioned studies are also not specifically 
mentioned in the survey. There were also a plethora of answer choices available for 
each question. These factors allowed participants to answer in an honest manner. 
They also remove possible skewing of the data due to patients being persuaded to 
choose a particular answer choice. Demographics of the respondents can be found in 
Table 1.  
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Table 1: Demographics of Subjects That Participated in the Online Survey 
Gender: n 
Participants 
Ethnicity: n 
Participants 
GH 
treatment 
duration: 
n Participants 
Male 14 Caucasian 74 t < 1 year 12 
female 72 Asian 3 t > 1 year 7   
Other 9 t > 2 
years 
30 
    
t > 5 
years 
12 
    
t > 10 
years 
25 
      
age: n 
Participants 
cause of GHD: n 
Participants 
  
18-23 6 Removal of 
pituitary tumor 
during childhood  
3 
  
24-29  3 Non-tumor derived 
childhood onset  
9 
  
30-39 28 Congenital 
panhypopituitarism 
6 
  
40-49  25 Congenital GHD 3 
  
50-59  15 removal of pituitary 
tumor during 
adulthood 
26 
  
60+  9 other 39 
  
 
The survey was analyzed using one-way ANOVAs which accessed the 
significance of the variance between responses chosen for each question. ANOVAs 
were created using the program Graphpad Prism. Each possible response was 
designated as a single group. Groups included a set number of values corresponding 
to the total number of individuals who answered the survey question. Values were 
either 1 which signified that the participant had picked the response designated with 
that group or 0 which signified that the designated response was not picked by that 
participant. The one-way ANOVAs specifically analyzed variance among the resulting 
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means of values in each group for a given question. Variance where calculated p 
values were below 0.05 indicated that the prevalence of response choice was unlikely 
to occur due to random chance. This result would imply that variance seen among 
response groups is statistically significant. Once statistical significance was 
determined, response choice prevalence was used to support or oppose literary 
findings.  
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Chapter 1: Growth Hormone’s Effects on Energy 
One question asked in the survey conducted for this thesis was “Has GH 
affected your level of energy?” The possible answers choices were: yes, I feel much 
more invigorated than I used to; yes, I feel that I might have a bit more energy than I 
used to; no, I notice no change in my average level of energy to perform tasks; Yes, I 
feel more easily fatigued after beginning GH therapy; and Yes, my degree of fatigue 
is so great that I find it difficult to get out of bed on most days of the week. The 
percentage of responses chosen can be seen in Figure 20 (Appendix A). ANOVA 
analysis (Figure 1) revealed that variance between selected answers was statistically 
significant (p < 0.0001).  
 
Figure 1. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 1 data. SI: strong increase; MI: 
moderate increase; NC: no change; MD: moderate decline; SD: strong decline. 
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Seventy six percent of those surveyed noticed improvement in their energy 
level after starting GH therapy. Nearly 32% of those surveyed said that their energy 
level had greatly increased. This subjective data supports that GH affects energy in 
some manner. The reasoning behind these effects will be discussed.  
Metabolism: 
 GH might regulate energy through its effects on metabolism. GH is known to 
affect the storage and breakdown of lipids and proteins (Mckinley 674). Adenosine 
triphosphate (ATP) is commonly referred to as the energy chemical as it is often used 
to aid the occurrence of reactions in cells. These reactions must always be occurring, 
or the cell will die. Thus, ATP is a necessary chemical. It can be made using 
carbohydrates, lipids, and proteins. The storage and breakdown of these molecules is 
thus incredibly important for survival. A 2009 study in the Journal Endocrine Reviews 
mentions that GH may be the primary metabolic hormone while fasting. 
Carbohydrates (e.g. glucose, fructose, lactose, and sucrose) are the primary 
macromolecules used to make ATP in cells. When glucose is unavailable, the body is 
able to use the building blocks of proteins and lipids to make ATP. GH is theorized to 
be the primary metabolic actor during a fasting state because it has been observed to 
be the only anabolic hormone that has an increased serum concentration during this 
period. The scientists who wrote the previously mentioned 2009 study concluded from 
a review of research on GH’s metabolic effects that GH increases lipolysis, decreases 
lipogenesis, and inhibits protein breakdown during a fasting state. This conclusion was 
supported by the fact that GH secretions during a fasting state caused serum 
concentration of free fatty acids (i.e. the fragments of fatty tissue used for ATP 
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production) to increase by 50%, caused a 50% reduction in urea production (i.e. a 
process caused partly by a need to remove nitrogen from proteins to make ATP),  and 
caused a 50% reduction of protein breakdown in humans (Moller and Jorgensen 159-
161). Untreated GHD patients often exhibit abdominal weight gain. This symptom 
appears to showcase an alteration in the metabolism of GHD patients. The increase 
in weight is theorized to occur due to a decreased breakdown of fats and an increased 
breakdown of lean muscle mass (Moller and Jorgensen 163). The body must use 
either lipids or proteins to make ATP in fasting conditions. Lipids are preferred over 
proteins because adipose tissue’s primary function is to store energy for later use. 
Proteins have other uses, so they are often the last resort option to produce ATP in 
normal patients. The increased abdominal weight and decreased muscle mass in 
GHD patients seems to indicate that proteins from muscle are being used instead of 
fats to make ATP in a fasting state. GHD patients thus have a 50% increase in protein 
breakdown and a 50% decrease of lipid breakdown. Without GH, the body does not 
properly utilize lipids to make ATP. Instead the body breaks down muscle tissue and 
increases the amount of stored fats. This can cause the patient to feel fatigued due to 
muscle breakdown and make them more susceptible to becoming obese. One 2002 
study in the Journal of Clinical Endocrinology and Metabolism researched how three 
years of GH treatment affected the body composition of 242 adult GHD patients. They 
found that GH treatment resulted in a significant increase in lean body mass of most 
GHD patients studied and a significant decrease in fat mass in the males with adult 
onset GHD (Attanasio et al. 1604). This indicates that GH could attenuate the effects 
of this abnormal usage of macromolecules seen in GHD patients. Thus, metabolism 
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research on GH suggests that GH treatment may be a necessary treatment to regulate 
the metabolism and energy level of GHD patients. Analysis of the survey conducted 
for this thesis will further evaluate whether GH can reverse these symptoms of muscle 
breakdown and weight gain due to lipid accumulation.  
“Has your weight changed since you began GH therapy?” Available answer 
choices were: yes, I have lost more than 45 pounds; Yes, I have lost more than 15 
pounds; No, my weight has not changed by more than 15 pounds; Yes, I have gained 
more than 15 pounds; and Yes, I have gained more than 45 pounds. The prevalence 
of response chosen for this question can be found in Figure 21 (Appendix A). ANOVA 
analysis (Figure 2) revealed that variance between selected answers was statistically 
significant (p < 0.0001). 
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Figure 2. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 2 data. L45: weight loss of more than 
45 pounds; L15: weight loss between 15 and 44 pounds; NC: no major change; G15: 
gained weight between 15 and 44 pounds; G45: weight gain of more than 45 
pounds. 
Nearly 13% of subjects said that they lost more than 45 pounds and 22.4% of 
subjects said they had lost between 15 and 44 pounds. Forty percent of subjects 
reported that their weight had not changed by more than 15 pounds. This large 
percentage may indicate that GH’s effect of increasing lean muscle mass and 
decreasing fat might result in no major in overall weight in some GHD patients. More 
objective research is necessary to corroborate this hypothesis. The fact that 35.3% 
subjects reported notable weight loss does support that GH has some effect on 
metabolism.  
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“Has your level of muscle mass been altered since you began GH therapy?” available 
answers choices were: yes, I have more muscle mass and I have spent months trying 
to increase my muscle mass; yes, I have more muscle mass, but my level of physical 
activity would not warrant this increase; no, I have noticed no change in my muscle 
mass; yes, I have less muscle mass than I used to, but I no longer exercise or lift 
weights as much as I used to; and yes, I have less muscle mass than I used to and 
my exercise regime has not changed. The prevalence of responses chosen for this 
question can be found in Figure 22 (Appendix A). ANOVA analysis (Figure 3) revealed 
that variance between selected answers was statistically significant (p < 0.0001). 
 
Figure 3. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 3 data. MW: warranted muscle mass 
increase; MUW: unwarranted muscle mass increase; NC: no change; LW: warranted 
loss of muscle mass; LUW: unwarranted loss of muscle mass. 
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This question was meant to evaluate whether GH treatment alone could 
increase muscle mass in GHD patients. Nearly 33% of those surveyed said that their 
muscle mass had increased after taking GH treatment even though they had not 
performed any exercises that might elicit this effect. This muscle mass increase is 
hypothesized to occur because their bodies have reduced the use of proteins to make 
ATP. This result supports that GH regulates metabolism through its effects on protein 
anabolism and catabolism.   
Physical Capacity: 
Endurance is another measurement of energy. GH might also affect an 
individual’s ability to exercise. A 2008 metanalysis in the Journal of Clinical 
Endocrinology and metabolism mentions that GHD patients often have reduced 
physical endurance due to a decrease in muscle strength and a 27% decline in the 
ability to properly utilize oxygen during exercise (i.e. measured via 𝑉𝑂2 max test) 
(Widdowson and Gibney 4413). Fortunately, GH treatment appears to attenuate these 
symptoms. The same 2008 metanalysis reviewed data collected from over 268 GHD 
patients that received GH treatment. Their analysis revealed that GH treatment on 
average caused maximal power output to increase by 40% and maximal oxygen 
utilization to increase by 34% (Widdowson and Gibney 4415). These results support 
that GH may be a necessary treatment for adult GHD patients to possess a healthy 
capacity to exercise. It also suggests that GH might regulate energy level via its effects 
on endurance.  
The survey conducted for this thesis also gauged subject endurance. “Has your 
physical endurance been altered by GH therapy?” The available answer choices were: 
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yes, I find that I am able to handle exercising for 30-75 minutes more than I did 
previously in one session; yes, I find that I am able to handle exercising for 10-25 
minutes more than I did previously in one session; I notice no large difference in my 
level of physical endurance; yes, I find that I must exercise for 10-25 minutes less than 
my previous length of exercise in one session; and yes, I find that I must exercise for 
30-75 minutes less than my previous length of exercise in one session. The 
prevalence of responses chosen for this question can be found in Figure 23 (Appendix 
A). ANOVA analysis (Figure 4) revealed that variance between selected answers was 
statistically significant (p < 0.0001). 
 
Figure 4. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 1 data. 30+I: 30 minutes or more 
increase; 10+I: 10-25 minute increase; NC: no change; 10+d: 10-25 minute decline; 
30+d: 30 minutes or more decline.  
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 Nearly 65% of those surveyed said that their exercise duration had increased 
by 10 or more minutes since they began GH therapy. Twenty five percent of those 
surveyed said that their exercise duration had increased by at least 25 minutes. These 
results support that GH may increase endurance in GHD patients.  
Mental Health: 
What has been discussed thus far has been a possible explanation for how GH 
might affect energy levels via its impact on both metabolism and endurance. Abnormal 
mental health can also affect energy levels. Many GHD patients report having 
depression, low Quality of Life (QOL), and anxiety when they are not on GH treatment. 
GH might also regulate energy through its effects on mental health. Three studies on 
this topic will be discussed.  
A 2005 study in the Journal of Hormones and Behavior researched the effects 
of GH therapy on memory and anxiety in GHD patients studied over a 10-year period. 
They used the State-Trait Anxiety Inventory (STAI) to measure whether GH treatment 
might reduce symptoms of anxiety. The STAI has resulting scores between 20 and 80 
where a higher score indicates more severe anxiety symptoms. A significant decline 
in scores from the baseline throughout the study indicated that, on average, GH 
treatment did reduce symptoms of anxiety (i.e. p < 0.05). The average baseline score 
was 35 and an average 6.4 point decrease was observed (Arwert et al. 347). This 
supports that GH treatment may attenuate anxiety symptoms in GHD patients. Further 
study on this topic should involve a larger sample size and the study of GHD patients 
with much higher STAI scores to determine whether GH could greatly reduce 
symptom severity in patients with more extreme anxiety.   
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If GH treatment can reduce anxiety in GHD patients, perhaps patients with 
GHD may be at an increased risk of having a mental disorder. A 2018 study published 
in the Journal of Growth Hormone and IGF Research evaluated whether children with 
GHD might be at an increased risk of having a mental health condition. The study 
reports that children with GHD may fail to mature psychologically, have a lack of self-
confidence, have poor social skills, and exhibit depressive symptoms. The objective 
of the study was to investigate the relation between GHD, anxiety disorders, and 
depression in youth. 122 minors with GHD and 122 healthy minors (i.e. aged 7–17) 
were studied. 87 GHD patients received GH treatment and 35 did not. The Kiddie 
Schedule for Affective Disorders and Schizophrenia for School-Age Children was 
primarily used to evaluate whether subjects had a mental health condition. Additional 
diagnosis tools were the DSM-V, the Children's Depression Inventory (CDI), the State-
Trait Anxiety Inventory for Children (STAI-C), and the Social Anxiety Scale for 
Children-Revised (SASC-R).  Generalized Anxiety Disorder (GAD) and Social Anxiety 
Disorder (SAD) were significantly more common in children with GHD compared to 
the control group (i.e. there were 20 more diagnosed cases of GAD and 11 more 
cases of SAD in GHD patients than in the control group). Depression diagnoses were 
smaller in the GHD group, but this difference was not statistically significant (Akaltun 
et al. 25-26). These results indicate that anxiety symptoms may appear more often in 
untreated GHD patients. A similar analysis should be conducted on adults to 
determine if this increased prevalence continues in adulthood.  
Since such a study does not yet exist, the next best thing is a subjective 2014 
study that asked 43 GHD patients (from either Germany, the United Kingdom, or the 
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U.S.) to describe the effects of living without growth hormone. The researchers posit 
that psychological impairment was most mentioned by the subjects (Brod et al. 4). 
Prevalent symptoms were feelings of depression and anxiety. Subjects also said that 
their condition caused them to be less socially active. GH treatment seemed to have 
attenuated these symptoms (Brod et al. 6-7). It is unknown whether the improvements 
reported by the subjects was merely a placebo effect. This study may lack substantial 
evidence to back the claims of its subjects, but it does provide an idea of what some 
adults with GHD could be experiencing. This data invites continued research on the 
topic.  
The survey conducted for this thesis also includes a question relating to mental 
health. “Has GH therapy affected your mental state? Select all that apply” The 
available answer choices were: yes, I once experienced anxiety, but I no longer 
experience those symptoms; yes, I once experienced sad feelings for months at a 
time, but those feelings have now ceased; no, I have a healthy mind and I have always 
had a healthy mind; I am not sure, I did have anxiety or clinical depression before 
starting GH treatment, but I take prescribed medications to attenuate those symptoms; 
yes, I have had increased anxiety since I began GH treatment; and yes, I have felt 
extreme sadness for a period lasting longer than a month since I began GH treatment. 
The prevalence of responses chosen for this question can be found in Figure 24 
(Appendix A). ANOVA analysis (Figure 5) revealed that variance between selected 
answers was statistically significant (p < 0.0001).  
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Figure 5. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 5 data. AA: attenuated anxiety; DA: 
attenuated depression; N: never experienced symptoms; U: unsure; AW: anxiety 
worsened; DW: depression worsened. 
Thirty four percent of subjects said that their symptoms of clinical depression 
had ceased after taking GH, but 6.2% admitted to having clinical depression 
symptoms after starting GH. Twenty three percent reported a decrease in anxiety 
symptoms and nearly 10% reported an increase in anxiety. GH dosage differences 
among patients could account for this difference between patient reported 
symptoms, but that is only a hypothesis. As previously mentioned, the questionnaire 
had a very small sample size, so its results do not accurately reflect similar qualities 
on the total population of adult GHD patients. It does however, invite further 
investigation on how GH treatment may affect the mental health of adult GHD 
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patients. The results do support that GH could attenuate depression and anxiety 
symptoms in some GHD patients. Understanding if this is indeed the case with a 
larger study and a possible investigation into the mechanism for how low GH causes 
anxiety and depression will surely support furthered GH treatment use for adult GHD 
patients.  
Sleep: 
Tiredness is an antonym of energy. GH might also be a necessary treatment 
for adults with GHD because it regulates the secretion of Growth Hormone 
Releasing Hormone (GHRH). It is important to mention that the Growth hormone 
secretion pathway is regulated by a negative feedback mechanism. This mechanism 
begins when the hypothalamus is stimulated to secrete GHRH. GHRH signals the 
pituitary gland to secrete GH and then GH signals the liver to produce IGFs. When 
serum concentrations of GH and IGFs become sufficient, both hormones will signal 
the hypothalamus to stop secreting GHRH (McKinley 671-674). This mechanism is 
brought to the forefront of discussion currently because the lack of regulation of this 
pathway in GHD patients has been observed to disrupt sleep. A 2009 study in the 
American Journal of Physiology researched how GHRH affected non-rapid eye 
movement (NREM) sleep in rats. What they discovered was that GHRH injections in 
the preoptic area of the hypothalamus significantly (p<0.001) increased NREM 
durations and significantly (p<0.001) increased EEG slow wave activity during sleep. 
They also found that GHRH antagonist hormone injections in the same area 
exhibited an opposite effect (Peterfi et al. 149-150). This supports that GHRH 
secretion levels heavily impact NREM sleep in mammals.  
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GH directly inhibits GHRH secretion and GH is always secreted during the 
initial 3rd and 4th stages of NREM in normal humans (qtd. in Peterfi et al. 147). These 
two facts could also possibly explain why untreated GHD patients often feel fatigued. 
Tiredness instead of physical or mental fatigue might contribute to this phenomenon. 
A 2010 study in the Journal of Endocrinology and Metabolism researched 
differences in reported tiredness, sleep stage durations, and EEG wave activity 
during sleep among 30 normal individuals and 30 untreated GHD patients. Pituitary 
specific (i.e. GH deficiency due to an inability of the pituitary gland to produce and 
secrete GH) GHD patients were shown to have significantly increased durations of 
NREM stages and significantly increased EEG slow wave activity compared to the 
control group. The increases in these more objective values were also associated 
with a high prevalence of reported poor sleep quality and tiredness during the day in 
those patients (Copinschi et al. 2198-2201). This data supports that GHD patients 
have altered sleep activity possibly due to a lack of GHRH secretion regulation by 
GH.  
 The same group who conducted the 2010 human sleep study also published 
a study in the European Journal of Endocrinology. This secondary study researched 
whether 10 of those same pituitary specific GHD patients had improved sleep after 
they were given GH treatment for 4 months. Differences in reported tiredness, sleep 
stage durations, and EEG wave activity were similarly measured in this study. The 
measurements attained from the 10 treated pituitary specific GHD patients were 
compared with measurements taken from 10 saline treated pituitary specific patients 
(i.e. which were also examined in the previous study). Seven participants had to 
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leave the study. A significant decline in average total sleep duration and a significant 
decline in EEG slow wave sleep activity were observed in the remaining GH treated 
subjects. Sleep duration was, on average, an hour shorter in GH treated patients 
than placebo treated patients (Morselli et al. 767-8). This difference in total sleep 
duration was relevant because sleep duration is dependent upon the time it takes for 
slow wave activity to reach minimum levels.  GH treated patients also reported being 
less tired. These researchers hypothesize from this resulting data that untreated 
GHD patients exhibit increased tiredness and longer sleep times because the signal 
to increase slow wave activity by GHRH is never turned off by GH. Thus, untreated 
GHD patients could feel fatigued because their brains are still in a deep sleep 
stimulating state.   
The latter study has limited significance due to its small sample size. A 
sample size of 13 subjects is not nearly enough to properly represent the total 
population of GHD patients. The survey conducted for this thesis included questions 
relating to sleep to possibly corroborate these claims with a larger sample size.  
“Have you noticed a change in your ability to sleep since you began GH 
therapy?” The available answers were: yes, once a week I will stay up for more than 
24 hours because I cannot sleep; yes, biweekly I will stay up for more than 24 hours 
because I cannot sleep; yes, once a month I will stay up for more than 24 hours 
because I cannot sleep; yes, I often get less than 7 hours of sleep per night because 
I toss and turn and am unable to fall asleep in an average amount of time; no, I 
notice no change in my ability to sleep; yes, I find it much easier to fall asleep and I 
often get 7 hours of sleep per night; yes, I find it incredibly easy to sleep and I often 
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get 8-10 hours of sleep per night; and yes, I find that I sleep too much and yet I 
never feel rested. The prevalence of responses chosen for this question can be 
found in Figure 25 (Appendix A). ANOVA analysis (Figure 6) revealed that variance 
between selected answers was statistically significant (p < 0.0001). 
 
Figure 6. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 6 data. Weekly: one day without any 
sleep weekly; biweekly: one day without any sleep biweekly; monthly: one day 
without any sleep monthly; 7h>: often less than 7 hours; nc: no change; o7h: often 7 
hours; o8-10h: often 8 to 10 hours; tms: too much sleep. 
 Nearly 40% of those surveyed reported that they can fall asleep easily and 
that they often get healthy amounts of sleep each night. Only 4 individuals reported 
that they sleep too often and yet never feel rested. These results support that GH 
therapy may be able to improve sleep ability and sleep quality in GHD patients.  
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Have you noticed any changes in your average sleep duration since you 
began GH therapy? The available answer choices were: yes, I find that I often wake 
up after an hour or 2 of being asleep; yes, I find that I often wake up after 3 to 4 
hours of being asleep; no, I notice no changes in my average sleep duration; and 
Yes, I find it extremely difficult to wake up after going to sleep. This question is 
meant to gauge if GH therapy might reduce sleep time to such a degree that might 
be detrimental to GHD patient health. The prevalence of responses chosen for this 
question can be found in Figure 26 (Appendix A). ANOVA analysis (Figure 7) 
revealed that variance between selected answers was statistically significant (p < 
0.0001).  
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Figure 7. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 7 data. 1-2 W: wake up after 1-2 
hours; 3-4 W: wake up after 3 to 4 hours. NC: no change; IW: impaired waking 
ability. 
Fifty seven percent of those surveyed said they did not notice a change in 
their average sleep duration. Twenty five percent of subjects said that they often 
wake up after three or four hours. These results support that GH therapy could 
cause some GHD patients to have unhealthy sleep durations. More research is 
needed to determine if this might be a possible side effect.  
Energy Conclusion: 
GHD has been observed to reduce patient 𝑉𝑂2 max, physical strength, 
endurance, lean body mass, and the serum concentration of free fatty acids. GHD 
has also been observed to increase body fat and sleep duration. Patients with GHD 
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also may have a higher incidence of anxiety and depression than the normal 
population. These patients also report that they never feel well rested. Energy can 
be affected by mental health, metabolism, endurance, and sleep. The discussed 
survey results and the mentioned studies support that GH could regulate energy via 
these four factors. Results also support that these symptoms can be attenuated via 
GH treatment. It is surmised from this data that GH is a necessary treatment for 
GHD patients because it appears to have a major effect on energy. These factors 
alone indicate that GH treatment is integral to the health of adult GHD patients, but 
there is much more to discuss to truly delineate why GH is a necessity.  
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Chapter 2: Growth Hormone’s Effects on Cognition 
The possibility of mental health effects caused by GH are just the tip of the 
iceberg when it comes to the effects of GH on the brain. This section will examine 
how GH might affect human cognition.  Scientists define cognition as an animal’s 
ability to process information (Nyberg and Hallberg 357). Processing information 
could thus also be broken down into two sub categories: memory and intelligence. 
Intelligence is the scale of one’s ability to understand a given topic in a certain 
amount of time and memory is the ability to retain that understanding for a given 
duration (Merriam-Webster.com). The definition of both concepts is generally 
understood though the actual mechanism for their action is currently being 
researched.  
Memory: 
Memory is easily quantifiable. One is either able to remember something or 
unable to remember that thing. This binary mutually exclusive aspect of memory 
makes it easy to detect changes in one’s ability to retain memories. Scientists have 
not reached a consensus regarding how memories work though. The current theory 
states that memories are unlike files in a computer. Memories are not stored in a 
specific place nor are they an independent component of the brain. On the contrary, 
memories are patterns of electrical signals among multiple synapses between 
neurons (Nyberg and Hallberg 357-8). GH could regulate memory formation via its 
effects on synaptic plasticity.  
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Research on mice has shown that GH is able to stimulate synaptic plasticity 
(i.e. the ability of synapses to alter their membrane potential) (Molina). This 
stimulation of synaptic plasticity is said to activate long term potentiation (i.e. 
prolonged transmission between two synapses based on previous electrical patterns 
experienced by the neuron), which plays a role in learning and long-term memory 
storage (Nyberg and Hallberg 357-8). Said stimulation is believed to be transmitted 
via glutamate receptors. When bound to glutamate, these receptors signal calcium 
and sodium channels to open which signal synaptic plasticity and an action potential. 
GH is theorized to play a role in the formation of different subunits that make up the 
glutamate receptor N-Methyl-D aspartate (NMDA). The theorized mechanism is 
thought to involve the JAK-STAT pathway. The JAK-STAT pathway is a common 
cellular signaling pathway that is often activated by cytokines. This pathway has 
three components: a receptor on the surface of the cell that binds to ligands such as 
cytokines or hormones, Janus kinases (i.e. a type of protein that adds a phosphate 
group to another protein to activate that protein), and STATs (i.e. signal transducers 
and activators of transcription). A signal cascade caused by the JAK-STAT pathway 
involves a ligand binding to the receptor which signals Janus kinases to 
phosphorylate the receptor using ATP. The newly phosphorylated receptor 
phosphorylates STAT molecules. When STATS are activated through 
phosphorylation, they form dimers and relocate to the nucleus where they will then 
modify the transcription of genes which alters protein production in the cell.  GH is 
said to bind to its receptor GHR which signals Janus Kinases to phosphorylate the 
receptor. This reaction causes the signal cascade mentioned above and causes 
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STAT dimers to then travel through the nucleus and bind to DNA to increase the 
transcription of genes associated with the NMDA receptor (i.e. GluN1, GluN2A and 
PSD‑95). GH is also theorized to stimulate the binding of glutamate to NMDA 
(Nyberg and Hallberg 360-3).  
GH may also play a role in synaptic plasticity through its effects on NF-kB 
activation. NF-kB has been theorized to play a role in the transformation of a short-
term memory to a long-term memory (Kaltschmidt). One study showed that crabs 
with inhibited NF-kB expression had significantly impaired ability to form long term 
memories (Merlo). GH has not been proven to increase NF-kB activation in the 
brain, but there is evidence that it stimulates NF-kB activation in other areas of the 
body. Multiple studies have found that GH does regulate NF-KB activation in the 
lungs, in adipose tissue, in macrophages, and other somatic cells (Liu, Jeay, and 
Kumar). It is hypothesized that GH may also regulate memory formation via the 
activation of NF-KB. Further research to test this hypothesis is needed, but the fact 
that GH can activate NF-KB in other areas of the body and the fact NF-KB regulates 
memory formation may indicate that there are more GH mechanisms that are 
important to memory maintenance. GH thus may play a role in ensuring proper 
memory formation in the mammalian brain via its ability to increase synaptic 
plasticity by possibly regulating NMDA receptors and NF-KB secretions.  
Intelligence: 
Intelligence does not yet have a discernible marker in the brain. The 
intelligence quotient is often used to determine one’s intelligence, but scientists are 
not yet sure of what causes one person to be more intelligent than another 
Hutchins 29 
 
individual. It is hypothesized that intelligence may have something to do with the glial 
cells of the CNS. The primary example that can support this conclusion lies in a 
1985 study on the genius, Albert Einstein’s brain. This study found that Albert 
Einstein’s brain only differed from other lower IQ brains in that it had more glial cells 
in a region of the brain that was believed to have a role in logic and mathematical 
reasoning (Diamond et al. 201-4). The following paragraphs will detail how GH might 
affect glial cells.  
 Scientists in Madrid, Spain discovered that GH may affect the development of 
astrocytes. They studied hypothalamus and hippocampus astrocytes. In this study 
they found that GH treatment on rat brains was found to increase the secretion of 
GFAP (i.e. a protein secreted specifically by differentiated astrocytes). This indicates 
that GH may cause immature astrocytes to differentiate. They theorized that GH 
played a role in the successful differentiation of these cells through its binding to 
plasma membrane GH receptors which signaled the activation of a PI3K/AKT 
pathway. The PI3K/AKT pathway is a cellular signaling pathway that is often 
activated by a growth factor ligand. Its signaling cascade involves a receptor tyrosine 
kinase, a phosphatidylinositide 3 kinase (PI3K), phosphatidylinositol 4,5-
bisphosphate (PIP2), mTOR, pyruvate dehydrogenase kinase 1 (PDK1) and 
Serine/Threonine protein kinase (AKT). The pathway begins as a growth factor (e.g. 
growth hormone) binds to the cell surface portion of 2 receptor tyrosine kinases that 
have dimerized. The receptor complex stimulates the autophosphorylation of the 
cytoplasmic side of the receptor tyrosine kinases. PI3K then binds to the 
phosphorylated tyrosine kinases. The receptor tyrosine kinase then phosphorylates 
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PI3K which phosphorylates PIP2 (PIP2 becomes PIP3 which stands for 
phosphatidylinositol 3,4,5-triphosphate). AKT then binds to PIP3 and is 
phosphorylated by either a PIP3 bound PDK1 or an mTOR complex. Activated AKT 
then may cause the cell to alter glucose metabolism, inhibit apoptosis (programmed 
cell death), alter gene transcription, stimulate cell differentiation, signal cell 
proliferation, alter GABA receptor expression, or activate NF-kB which has been 
shown to play an important role in both synaptic plasticity and immune system 
regulation. In summary, GH may cause astrocytes to differentiate through this 
cellular pathway. Growth hormone releasing peptides were also shown to signal the 
astrocytes to multiply in number through the same PI3K/AKT pathway. These 
scientists corroborated their assumptions by preventing the ligand binding of GH and 
GHRPs to their receptors on the astrocytes and found the side effects mentioned 
above to be reversed. The same effect was observed when PI3k activation was 
blocked (Baquedano et al. 266-272). This supports that GH and the peptides 
associated with it, could play a role in the division and development of astrocytes.  
Oligodendrocytes 
A joint study between Wake Forrest University and University of Oklahoma 
found that GH helps regulate the production and survival of oligodendrocytes. 
Corpus callosum oligodendrocytes in rats with growth hormone deficiency were 
researched. These scientists found that the GH deficiency inhibited the creation of 
new cells. Two weeks after the cessation of GH treatment, the size of the newly 
created group of immature oligodendrocytes had been 25% fewer than past 
observed groups. GH deficiency was also found to inhibit the survival of new 
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oligodendrocytes. The two effects led to a 30% decrease in the total population of 
oligodendrocytes in the corpus callosum (Hua et al.1064-6). These results indicate 
that GH stimulates the proliferation and successful survival of oligodendrocytes in 
some manner. The scientists theorized that this drop in the oligodendrocyte 
population (i.e. due to a decrease in GH and IGF-1) might be a cause of the 
cognitive decline that occurs due to aging (Hua et al. 1068). GH secretion naturally 
declines as one ages, and thus the possible reduction in these myelinating agents 
would decrease the speed of signaling between neurons. This notion is supported by 
another study which found that normal elderly patients with the best cognitive ability 
out of those tested were shown to produce more GH than the other subjects (Quik et 
al.). GH thus may influence intelligence through its role in regulating oligodendrocyte 
proliferation and survival rate.  
GH may regulate memory through its effects on synaptic plasticity, and GH 
may affect intelligence by stimulating the proliferation and differentiation of glial cells. 
What may be equally as important in discerning how GH affects cognition are 
studies on the clinical manifestations of the absence of and use of GH treatment in 
GHD patients in relation to cognitive functioning. The above list of possible 
mechanisms for how GH might affect cognition are somewhat meaningless without 
studies that examine whether cognitive function is even altered in GHD patients. 
Clinical testing for changes in intelligence and memory will now be discussed in the 
form of IQ and memory differences among GHD patients without GH treatment, 
GHD patient that receive GH treatment, and healthy individuals.  
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Clinical Manifestations: 
A group of pediatric endocrinologists from the Netherlands endeavored to 
study children treated with GH due to them being vertically challenged. They 
endeavored to determine if GH had any additional functions besides increased 
height. Fifty-three children took an Intelligence Quotient examination throughout an 
8-year GH treatment period.  IQ was shown to increase at a statistically significant 
rate throughout the treatment with mean scores either coming close to or surpassing 
the average scores of the general population (Chaplin et al. 395-8) These results are 
promising, but more data is needed to truly determine if GH increases IQ in GHD 
patients. IQ does change slightly during childhood, which could skew the data they 
found. An adult study of the same nature is needed to truly determine if GH has the 
ability to increase IQ.  
Members of the Neuropsychology department at the University of Amsterdam 
studied 30 GHD adults with an age range between 42 and 76. They tested the 
adults’ working memory and learning ability. Low dose patients were found to have 
deteriorated memory and learning ability at the end of the four-year session. High 
dose patients had means higher than baseline in both aspects at the end of the four-
year session (Deijen et al. 4) This difference may be because entrance of GH past 
the blood brain barrier is dependent on dosage (Nyberg and Hallberg 359). The 
large age range and small survey size limit what can be concluded from the study 
though.  
The same group also studied 23 GHD adult men for a ten-year period. This 
study was previously mentioned because it also researched mental health in GHD 
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parents. These scientists also endeavored to learn about growth hormone’s effects 
on mood memory in GHD patients. They found that the patients’ short term memory 
began to improve after one year, while long term memory improved after two years. 
Both memory types were found to improve for the first five years of treatment. 
Memory tests were never similar, so patients could never prepare for said 
examinations. The scientists were forced to reduce the GH dosage administered 
during the final five years. The final tests at the end of the period showed memory 
scores below the fifth-year scores, but above the baseline and all other test scores 
(Arwert et al. 347). This result supports the previously mentioned dosage blood brain 
barrier theory. The Survey size might be too low to be representative of GH’s effects 
on all GHD patients, but these results support that GH could play a prominent role in 
memory function. 
A 2006 meta-analysis in the Journal of Psychoneuroendocrinology analyzed 
multiple studies that tested memory impairment difference between untreated GHD 
patients, treated GHD patients, and normal patients. Altogether the analysis studied 
more than 300 patients. What they found was that untreated GHD patients had 
much worse memory than those of the normal population. They also found that GH 
treatment typically attenuated these symptoms. Moderate improvement of memory 
was observed after 6 months of GH treatment, but the GHD treated patients were 
never observed to have equal memory capacity with those of the normal patients 
(Falleti et al. 685-9). 
The survey conducted for this thesis also gauges the clinical manifestations of 
cognitive impairment in GHD patients. This was done by asking patients about how 
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they felt GH has affected their different cognitive abilities. “What is your highest level 
of academic achievement?” Available answer choices were: Less than a high school 
diploma, High school diploma, Some college, Associates, Bachelor’s, Master’s, 
Doctorate, and Post Doctorate. This question was meant to gauge intelligence. An 
IQ question would have been more quantitative, but it was doubtful that most 
subjects would be aware of their IQ. Intelligence is all about learning ability and 
those who learn better are more inclined to do well in their collegiate pursuits. The 
prevalence of responses chosen for this question can be found in Figure 27 
(Appendix B). ANOVA analysis (Figure 8) revealed that variance between selected 
answers was statistically significant (p < 0.0001). 
 
Figure 8. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 8 data. LHS: less than high school 
diploma; HS: high school diploma; SC: some college; A: associates degree; B: 
bachelor’s degree; M: master’s degree; D: doctorate; PD: post doctorate. 
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 A 2010 Harvard University and Asian Development Bank study found that 
6.7% of the global population had a college degree of some kind (Barro and Lee 32). 
The latest American census mentions that 33.4% of the American population has a 
bachelor’s or higher degree (qtd. in Alonzo). Fifty seven percent of those surveyed 
have college degrees of some kind. Forty three percent of respondents attained a 
bachelor’s or higher degree. A limitation of this question is that it does not establish if 
GH was taken during matriculation periods. The significance of these results is 
inhibited by this limitation. The results somewhat support previous findings that GH 
might increase intelligence. The next question delves further into how GH might 
affect school performance.  
“If you are a student, do you feel that growth hormone treatment has affected 
your school performance?” Available answers choices were: yes, my grades have 
improved slightly since I began GH treatment; yes, my grades have improved 
significantly since I began GH treatment; I have witnessed no change in my 
academic performance since taking growth hormone injections; yes, my grades have 
declined slightly since I began GH treatment; and yes, my grades have declined 
significantly since I began GH treatment. This question has much fewer responses 
because only 30 of the 86 participants were currently in school. The significance of 
the results is minimal due to the small sample size but they do invite further testing 
regarding this topic. As was already discussed, GH seems to play a role in 
regulating memory formation and intelligence. It would be difficult to argue that each 
of these factors are not integral to getting good grades in school. Thus, the question 
can be used to subjectively assess the quality of those factors. The prevalence of 
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responses chosen for this question can be found in Figure 28 (Appendix B). 16 
individuals reported no effect, 12 reported improvement, and 2 reported decline. 
ANOVA analysis (Figure 9) revealed that variance between selected answers was 
statistically significant (p < 0.0001).  
 
Figure 9. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 9 data. N: no change; SI: strong 
improvement; MI: moderate improvement; SD: strong decline; MD: moderate 
decline. 
Forty percent of those who responded say that their grades improved. These 
results somewhat support that GH therapy can attenuate cognitive decline 
symptoms in GHD patients. The next question focuses specifically on memory.  
“Has GH treatment affected your memory?” Available answers choices were: 
yes, GH has strengthened my short-term memory. I have an easier time memorizing 
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phone numbers and other lists of 7-10 letters and numbers after a couple of minutes; 
Yes, GH has strengthened my long-term memory. I have an easier time recalling 
concepts or scheduled tasks that I have tried to memorize and remember for a 
period lasting longer than 1 day; No, I have noticed no change in my ability to store 
and retain memories following the inception of my growth hormone therapy; Yes, GH 
has weakened my short-term memory. I find it difficult to memorize phone numbers 
and other lists of 7-10 letters and numbers after a couple of minutes; and yes, GH 
has weakened my long-term memory. I find it harder to recall concepts or scheduled 
tasks that I have tried to memorize and remember for a period lasting longer than 1 
day. The prevalence of responses chosen for this question can be found in Figure 
29 (Appendix B). ANOVA analysis (Figure 10) revealed that variance between 
selected answers was statistically significant (p < 0.0001). 
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Figure 10. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 10 data. SST: strengthened short-
term memory; SLT: strengthened long-term memory; NC: no change; WST: 
worsened short-term memory; WLT: worsened long-term memory. 
 More than 25% of those surveyed mention that GH has improved both their 
short-term and long-term memory. Less than 6% mentioned that their ability to form 
long-term and short-term memories had worsened after they started GH. Such a 
discrepancy without any prompting of the subjects supports that GH treatment might 
improve memory in GHD patients.  
These discoveries on how GH effects cognitive ability in GHD patients have 
incentivized some scientists to test if GH could enhance cognitive recovery in the 
normal population. GH may also serve roles that directly affect neurons. Research 
shows that GH acts as a neurotropic factor. Neurotropic factors are peptides that 
stimulate the development and differentiation of neurons. These factors are also 
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believed to increase the survival of neurons. Their method of action is through 
tyrosine kinase (i.e. mostly receptor tyrosine kinases such as the one in the 
previously mentioned PI3K/AKT pathway). Neurotropic factors were also observed 
to stimulate the reparation of damaged neurons in vitro (Malenka 211-221). GH’s 
use as a treatment for cognitive impairment in non-deficient patients is still being 
researched though. At present there are a few case studies and some murine 
experiments that indicate that GH can attenuate the symptoms of brain damage.  
One murine study researched the use of growth hormone as a treatment to 
attenuate cognitive impairment in stroke (i.e. a condition characterized by the death 
of neural tissue due to a lack of blood flow to the affected area) induced mice. Mice 
were given GH for 28 days 48 hours after the stroke was induced. GH-treated mice 
had a better learning capacity over control groups. GH-treated mice were also 
observed to have significantly less neural tissue death. Other neurotropic factor 
populations were also raised in GH treated mice. Factors which indicate the creation 
of new synapses (i.e. Synapsin-1) and the remyelination (i.e. Myelin basic protein) of 
neurons were present in much higher numbers in the stroke affected tissue of GH 
treated mice. CD31 and collagen-IV which indicate the presence of vascular tissue 
were also higher in number and present in more areas of the stroke affected tissue 
in GH treated mice (Ong et al. 1257-1266). In summary, these scientists found that 
GH could be a potential treatment for stroke victims because it was observed to 
promote cognitive and neuronal recovery.  
A human case study found that GH treatment was able to repair nerve 
damage in a 61-year old man (i.e. with a normal functioning pituitary gland) that 
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abused opioids. They found that GH was able to reduce the apoptosis of neural 
tissue and promote the regeneration of neurons in the patient (Rhodin et al. 760-3). 
As a case study these results provide insight into how GH treatment could benefit 
similar patients, but it does not indicate without a doubt that this same positive end 
result would be seen in similar patients.  
Another human case study observed the effects of GH treatment in addition 
to neurorehabilitation techniques to improve the cognitive capabilities of a plane 
crash victim. The 18-year-old male patient was treated fifteen months after the 
incident and was observed to have a nearly destroyed right hemisphere. The man 
had a severe case of traumatic brain injury. Growth hormone was chosen as a 
treatment because it was previously shown to stimulate neurogenesis and 
angiogenesis in rats and it did not seem to have the negative effects generally 
associated with the use of other neurotropic factors.  He received two years of 
treatment with a dosage of 1mg per day. Before treatment, he was unable to walk or 
speak. He was able to sign himself out of the hospital at the end of treatment. On a 
five-point scale, the patient was shown to have a 3-point increase in speech ability 
and a 4-point increase in mobility (Devesa et al. 30472-30480).  
Another case study observed the effects of GH treatment accompanied by 
typical neuro rehabilitative techniques on a cognitively impaired child. The subject 
was a 10-year-old female who had acute perinatal asphyxia during her birth. The girl 
had normal pituitary function but was treated with GH to possibly improve her 
cognitive capabilities. She received a dosage of 0.5 mg per day for three months 
and later 1.2 mg every three days. Her traditional neurorehabilitation involved 
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occupational therapy, speech therapy, and auditive therapy. The study lasted 9 
months. Following treatment, her IQ increased by 29 points. The research group 
observed that she was at her grade level in most subjects after completing the 
treatment (Devesa et al. 2-7).  
Attention: 
The above studies and survey results support that GH effects cognition and 
may be an effective treatment to attenuate cognitive decline. What has yet to be 
discussed is whether GH might affect abilities related to cognition. Untreated GHD 
patients may also have trouble focusing. The previously mentioned 2006 meta-
analysis also gauged improvements in attention after GHD patients started GH. Data 
from more than 300 patients was analyzed. Attention capability was significantly 
worse in untreated GHD patients than in the healthy patients. The measured factor 
with largest discrepancy between the two groups was attention. The analysis also 
found that GH treatment had led to moderate or large improvement (after 6-9 
months) in the attention capabilities of GHD patients (Falleti et al. 685-9). These 
results support that GH could regulate attention to some degree. The previously 
mentioned 2018 article in the Journal of Growth Hormone and IGF Research 
contradicts the meta-analysis findings though. It found no significant difference in the 
prevalence of ADHD in minors with GHD (Akaltun et al. 25-26). This would support 
that GHD does not cause ADHD.  
Clinical manifestations of attention abnormalities in GHD patients yield 
inconclusive results. It may be better to discern the effect of GH on attention by 
looking at the mechanisms involved. A 2001 study found that attention can be 
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modified via NMDA receptors (Turchi and Sarter 103-117). The importance of GH 
regarding these receptors has already been discussed. It is possible that GH could 
regulate attention through its effects on NMDA receptors. GH secretion might also 
be altered by ADHD medication. A 2003 study in the Journal of Child and 
Adolescent Psychopharmacology researched how the ADHD medication guanfacine 
effects growth hormone secretion in children with ADHD. Eight children with ages 
ranging between 8 and 10 were studied. Patients either had ADHD with reading 
disabilities or only ADHD. Guanfacine treatment caused GH secretion amounts to 
significantly increase for both groups. Those with only ADHD had even higher GH 
secretions (Halperin et al. 287-291). The lower GH increase in patients with reading 
disabilities might further support that inhibition of GH secretion may contribute to 
cognitive abnormalities. The more novel result of the study is the fact that a 
medication for ADHD somehow affects the mechanism for GH secretion. Such a 
small sample size fails to represent the larger population of individuals with GHD, 
but it does support that there could be a relationship between GH and attention. The 
questionnaire attempts to further evaluate the clinical manifestations of these effects 
on attention.  
The prevalence of responses chosen for this question can be found in Figure 
30 (Appendix B). 15 of the 86 subjects reported being diagnosed with ADHD. The 
2018 study mentioned above found 7 of the 122 GHD patients and 6 of the 122 
healthy patients to have ADHD. When compared to the 2018 study, the survey 
responses support that there may be increased prevalence of ADHD in adults with 
GHD. The smaller sample size limits one’s ability to discern whether this is true of 
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the larger GHD population though. The next question gauges improvement of 
attention in those surveyed.  
 Increased focus duration should be directly caused by improvement in 
attention capability. The prevalence of responses chosen for this question can be 
found in Figure 31 (Appendix B). Thirty-five individuals reported having improvement 
in their ability to focus. Twelve of those 35 reported that their focus duration 
improved by two hours. Forty-four noticed no change and 5 reported decline in focus 
duration. ANOVA analysis (Figure 11) revealed that variance between selected 
answers was statistically significant (p < 0.0001).  
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Figure 11. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 12 data. 2I: 2 hour increase; 1I: 1 hour 
increase; .5I: 30 minute increase; .25I: 15 minute increase; NC: no change; .5d: 30 
minute decline; 1d: 1 hour decline; .25d: 15 minute decline; 2d: 2 hour decline.  
 
It is possible that the effects noticed by these patients could have also been 
caused by the placebo effect. The likelihood of this being the case was combatted 
by the wording of the question. It was not asked if GH improved attention. Subjects 
were only asked to describe if there were any changes in attention. The 35 
individuals that said they had improved attention were not in any way prompted to 
come to such a conclusion. The fact that 41.7% of subjects independently concluded 
that their attention span improved after taking GH supports the validity that GH 
affects attention in some manner.  
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Cognition Conclusion:  
In tandem, there exist possible mechanisms for how GH might effect 
cognition; known examples of GHD patients without treatment being cognitively 
impaired; known examples of GH treatment improving cognitive capacity in both 
GHD patients and in patients with brain injuries; known examples of GH being used 
to repair nervous tissue, known examples that GHD patients appear to struggle with 
poor attention capabilities, and known examples that GH treatment can attenuate 
those low attention symptoms. This plethora of data was supported by the 
questionnaire responses. Growth hormone could be integral to nervous system 
functioning. Not all is known about how GH secretion affects nervous tissue, but 
available data does certainly provide just enough information to invite furthered 
study. GH must hold some importance, or the previously mentioned effects would 
not be reported. Evidence suggests that many GHD patients could exhibit cognitive 
decline without treatment. It is supported by previously mentioned data that GH can 
improve cognition in GHD patients. New research also suggests GH could be a 
treatment to restore nervous tissue function and attenuate cognitive impairment in 
normal patients. It could be argued that GH is more important for cognitive 
functioning than it is for bone elongation.  
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Chapter 3: Growth Hormone’s Effects on Other Bodily Functions 
GH might also have effects on other organ systems. Most organ systems 
contain cells with Growth Hormone Receptors (GHRs), so it possible that GH can 
regulate more unmentioned mechanisms. GH’s possible effects on the 
cardiovascular system, the integumentary system, thermoregulation, wound 
regeneration, and the immune system will now be discussed.   
Cardiovascular System:  
 Recent research supports that GH could affect cardiac structure and some 
aspects of cardiovascular function. GH may affect blood pressure via its regulatory 
effects on nerves. This is theorized because GHD patients have been observed to 
have overactive sympathetic nerve signaling to vasculature smooth muscles. Such 
an observation indicates that GH could lower blood pressure by decreasing 
peripheral resistance. This is further supported by recent findings that show that this 
symptom of overactive sympathetic nerve activity was observed to be attenuated 
after one year of GH treatment (Isgaard et al. 26). While this mechanism for how GH 
could affect blood pressure is credible, clinical manifestations of blood pressure 
alteration due to GH are inconclusive.  Some studies indicate that GHD patients had 
hypertension that can be attenuated with GH treatment. Other studies found that GH 
did not affect blood pressure (Isgaard et al. 26). This indicates that more research is 
necessary to truly discern GH’s effects on blood pressure.  
The effects of GH on heart structure and function appear to be more 
conclusive. GHD patients without treatment were observed to have a smaller left 
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ventricular mass and decreased cardiac output (Isgaard et al. 27). Cardiac output 
was observed to be lower than normal patient control groups by an average of 17% 
while resting and by 29% during exercise in GHD patients younger than 40. GH 
treatment was observed to boost cardio-myocyte growth, improve systolic and 
diastolic cardiac function, increase stroke volume, increase heart rate, and increase 
left ventricular mass size (Isgaard et al. 28). Such observations support that GH may 
be necessary to maintain healthy cardiac function. Untreated GHD patients were 
also observed to have an average 40% increased risk of having a heart attack in a 
study with sample size of 1411 GHD patients. Another study with a sample size of 
289 GHD patients observed that those treated with GH were at a lower risk of having 
a heart attack than normal patients (Isgaard et al. 29-30). Such observations support 
that GH may be necessary to maintain healthy cardiac function. 
The survey conducted for this thesis also includes questions relating to the 
cardiovascular system. The first question asked patients to detail if they had a heart 
condition. Have you been diagnosed with any heart abnormalities? Available answer 
choices were: yes, I have some heart abnormalities and I was diagnosed with such 
conditions after being diagnosed with GHD; yes, I have some heart abnormalities 
and I was diagnosed with such conditions before being diagnosed with GHD; and I 
do not have any diagnosed heart abnormalities. The prevalence of responses 
chosen for this question can be found in Figure 32 (Appendix C). ANOVA analysis 
(Figure 12) revealed that variance between selected answers was statistically 
significant (p < 0.0001). 
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Figure 12. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 13 data. HA: have acquired after; 
HB: have acquired before; NHC: no known heart condition. 
 Eighty seven percent of those surveyed reported that they did not have any 
diagnosed heart abnormality. This result opposes that GHD patients have altered 
cardiac structure that contributes to major cardiac dysfunction.  
The second cardiovascular question gauged how GH treatment affects 
cardiovascular vital signs. Has your heart rate or blood pressure changed 
significantly since you began GH therapy? Subjects were asked to select all answers 
that applied to their current condition. Available answer choices were: yes, my 
resting heart rate has increased by more than 20 beats per minute; yes, my systolic 
and diastolic blood pressure are both 20 mm Hg higher than they were before I 
began GH therapy; yes, I now have hypertension; no, there has been no change in 
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my heart rate; no, there has been no change in my blood pressure; yes, my resting 
heart rate has decreased by more than 15 beats per minute; yes, my systolic and 
diastolic blood pressure are both 20 mm Hg lower than they were before I began GH 
therapy; and yes, I now have hypotension. The prevalence of responses chosen for 
this question can be found in Figure 33 (Appendix C). ANOVA analysis (Figure 13) 
revealed that variance between selected answers was statistically significant (p < 
0.0001). 
 
Figure 13. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 14 data. IH: increased heart rate; 
IBP: increased blood pressure; HYT: hypertension; NC HR: no change in heart rate; 
NC BP: no change in blood pressure; DH: decreased heart rate; DBP: decreased 
blood pressure; HOT; hypotension. 
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 More than 50% of those surveyed said that GH treatment did not affect their 
blood pressure or heart rate. No other response choices were chosen by more than 
10% of the subjects. These results do not oppose or support if GH effects 
cardiovascular vital signs.  
Skin: 
Recent findings suggest that GH also regulates integumentary system 
functions. A 2016 article in the Journal of Reviews in Endocrine and Metabolic 
Disorders that focused on this on topic will be discussed. The researchers examined 
how both hyper secretion (acromegaly) and hypo secretion (GHD) of GH affected 
skin health. Acromegaly patients are observed to have hyperhidrosis (i.e. excess 
sweat secretion), thick skin, skin roughness, the appearance of skin growths known 
as acrochordons, and excessive oil secretions by sebaceous glands (Gantenbein et 
al. 261). GHD patients often have hypohidrosis (i.e. diminished or a complete 
absence of sweat secretions) and skin that is thin and dry (Gantenbein et al. 264). 
The scientists responsible for this review mention that this near ubiquitous 
appearance of these symptoms in patients with altered GH secretion could be used 
in the future to diagnose both conditions (Gantenbein et al. 265). This apparent high 
prevalence of symptoms suggests GH regulates the integumentary system in some 
way. Furthered corroboration of this notion is the fact that nearly all integumentary 
cells possess GH receptors (Gantenbein et al. 259). 
The survey conducted for this thesis also includes questions relating to the 
integumentary system. The first asked “Have you noticed any changes in your skin 
since you began GH therapy?” The available answer choices were: yes, I have 
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noticed a thinning of my skin since I began GH therapy; yes, I have noticed an 
increase in the dryness of my skin since I began GH therapy; yes, I have noticed an 
increase in the elasticity of my skin since I began GH therapy; no, I have noticed no 
changes in my skin; yes, I have noticed a thickening of my skin since I began GH 
therapy; yes, I have noticed a decrease in the dryness of my skin since I began GH 
therapy; and yes, I have noticed a decrease in the elasticity of my skin since I began 
GH therapy The prevalence of responses chosen for this question can be found in 
Figure 34 (Appendix C). ANOVA analysis (Figure 14) revealed that variance 
between selected answers was statistically significant (p < 0.0001). 
 
Figure 14. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 15 data. Thin: thin skin apparent; ID: 
increased dryness apparent; NC: no change; Thick: thick skin apparent; DD: 
decreased dryness; DE: decreased elasticity.  
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 Fifty six percent of patients reported no noticeable change in their skin since 
they began GH therapy. Reports of increased skin thickness and dryness were 
roughly equal to reports decreased thickness and dryness. This data may indicate 
that current GH treatment may be ineffective at reducing symptoms of thin and dry 
skin. More research is needed to determine if this is true.  
The second question focuses on sweat. “Has your ability to sweat been 
affected by your growth hormone treatment?” The available answer choices were: 
yes, I sweat a lot more now that I administer GH injections; yes, I sweat a lot less 
now that I administer GH injections; no, I have noticed no change in my perspiration 
rates since I began Growth Hormone treatment; and I am unsure because I have not 
thought about my rate of perspiration until now. The prevalence of responses 
chosen for this question can be found in Figure 35 (Appendix C). ANOVA analysis 
(Figure 15) revealed that variance between selected answers was statistically 
significant (p < 0.0001).  
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Figure 15. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 16 data. IS: increased sweating; DS: 
decreased sweating; NC: no change; UK: unknown.  
Twenty five percent of subjects said that GH therapy has caused them to 
sweat much more than they used to. This result supports that GH therapy might 
increase sweating ability in some GHD patients.  
The importance of skin health may not be as well-known as that of cognitive 
and heart health. It should be mentioned that the integumentary system is the first 
line of defense against harmful agents (e.g. chemical toxins and pathogens) and a 
regulator of body temperature. Aspects of the skin such as thickness and oil 
lubrication are integral to the prevention of harmful agents entering the body. Sweat 
secretion benefits temperature regulation. Merocrine glands are the exocrine glands 
that secrete sweat which is 99% water and 1% electrolytes. To properly illustrate 
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sweat’s importance, its role in attenuating temperature increase during exercise will 
be described. Muscles release excess heat during exercise because they are 
working harder and using more energy. Excess heat causes blood temperature to 
increase. Peripheral blood vessels will dilate to transfer heat to the skin surface. 
Heat does not easily escape through the skin to the atmosphere without another 
participating molecule. This molecule is the water from the sweat. Merocrine glands 
will begin to secrete sweat when body temperature increases. The heat is then 
transferred from the skin to the sweat. This causes a lot of the sweat to evaporate. 
Evaporation of sweat allows heat to be more easily removed from the body. Thus, 
sweat is integral to proper thermoregulation in humans. The role of GH in regulating 
the skin is important to the overall health of an individual 
Thermoregulation: 
The fact that GH deficiency causes hypohidrosis may indicate that GHD 
patients are at an increased risk of hyperthermia. In 1995, Researchers from the 
University of Copenhagen performed a controlled study on sweating and body 
temperature regulation during exercise in the heat. Sixteen GH-treated GHD patients 
and 10 healthy subjects were studied. Each subject exercised on a bicycle 
ergometer for 60 minutes at a workload corresponding to 45% of their individual 
maximal oxygen consumption (𝑉𝑂2 max), in a room maintained at 35C°. GH serum 
concentrations increased significantly after approximately 10 min of exercise in the 
normal subjects (P < 0.001) but remained low in the GHD patients. Skin temperature 
increased significantly during exercise in the GHD patients but remained unaltered in 
the healthy subjects (Hjortskov et al. 3337-8).  
Hutchins 55 
 
These results support that GH-deficient patients may be at risk for developing 
hyperthermia during physical activity in hot environments. It also indicates that the 
traditional GH treatment of one injection every evening may not truly attenuate all of 
the symptoms of GH deficiency.   
A more recent study concerning the same topic was published in 2014. In it, 
researchers recorded the variance of water loss, blood plasma volume, and blood 
serum HGH in 8 highly trained triathlon athletes between resting and high impact 
exercise states. All subjects had normal functioning pituitary glands. The athletes 
were subjected to 2 exercise tests consisting of 20 minutes of running and 20 
minutes of cycling separated by a break period of 30 seconds. The exercise 
environment was such that each participant was performing at a level where their 
bodies were consuming oxygen at rate that was 75% of its maximal value.  Subjects 
were divided randomly to either do cycling then running or running then cycling. 
These individuals then returned after two weeks to perform the test in reverse order 
of what they had done previously. Water loss was estimated by weighing the 
subjects before and after each trial. Plasma volume and GH serum level were 
recorded at rest and after each phase of a trial. The importance of cycling and 
running was to test the researchers own hypothesis. They hypothesized that GH 
secretion might be inhibited during exercise by baroreceptors and a known 
baroreceptor reflex involved the quick transition from the angle the body is at while 
cycling and the angle the body is at when running (Galy et al. 1). Plasma volume 
and water loss were recorded to observe how the alteration of GH secretion might 
affect sweat regulation. Measurement of water loss indicated the degree of sweat 
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produced throughout a trial. Measurement of plasma volume is used in addition to 
water loss detection because sweating causes merocrine glands to increase plasma 
filtration which decreases plasma volume. Therefore, increased sweating was 
detected via decreased plasma volume and decreased sweating was detected via 
increased plasma volume. Average water loss was significantly lower in the 
cycling1st-running2nd (C1R2) trial than the water loss amount after the running1st-
cycling2nd (R1C2) trial. A significant negative correlation was also observed 
between plasma volume and serum HGH levels. As HGH increased in the blood, 
plasma volume decreased further and further from the resting baseline. Perhaps the 
most notable observation was that the C1-R2 trial (i.e. which was designed to elicit 
the baroreceptor reflex) had a significantly lower serum HGH concentration at the 
end of R2 than the HGH concentrations recorded for C2. R2 plasma volume was 
also above resting baseline. C1, C2, and R1 plasma volumes were all lower than the 
resting baseline (Galy et al. 4-5). This indicates that the reflex significantly inhibited 
sweat secretion. In tandem, the results of the experiment support the researchers’ 
initial hypothesis that baroreceptors inhibit GH secretion during exercise. The results 
also further support that GH increases sweating during exercise.  
The results of these studies support that GH regulates thermoregulation 
through its effects on the integumentary system. Baroreceptors seem to inhibit this 
response, but the full mechanism for how GH elicits these effects is not yet known. 
What is known is that the hypothalamus regulates body temperature and secretes 
GHRH to stimulate the secretion of GH. Merocrine glands also have GH receptors 
(10 of triathlon study). These correlations could allude to a possible pathway for how 
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GH regulates sweating. The hypothalamus might receive signals that indicate that 
body temperature is increasing and react to those signals by increasing GH 
secretion via GHRH in order to stimulate merocrine glands to secrete more sweat. 
More research is needed to determine if this possible pathway is true. 
The survey conducted for this thesis also has a question relating to 
thermoregulation. “Has your sensitivity to heat exposure been altered by GH 
therapy?” The available answer choices were: yes, I feel that I am more susceptible 
to heat stroke after beginning GH treatment; yes, I feel that I am less likely to 
succumb to heat stroke after beginning GH treatment; no, I notice no change in my 
heat sensitivity; and no, I am not heat sensitive and I have never had a sensitivity to 
the heat. The prevalence of responses chosen for this question can be found in 
Figure 36 (Appendix C). ANOVA analysis (Figure 16) revealed that variance 
between selected answers was statistically significant (p < 0.0001). 
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Figure 16. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 17 data. ISH: increased sensitivity to 
heat; DSH: decreased sensitivity to heat; NC: no change; NP: Never experienced a 
problem with heat sensitivity. 
 Six percent of those surveyed reported that they never were heat sensitive. 
This indicates that 94% of those surveyed are heat sensitive. This result supports 
that GHD patients may be at an increased risk of hyperthermia. Nearly 55% of those 
surveyed said that GH therapy did not affect their heat tolerance. Twenty five 
percent of those surveyed reported having decreased heat tolerance since they 
started GH therapy. These results support that current GH treatment measures may 
not attenuate heat sensitivity in all GHD patients.  
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Regenerative Effects: 
GH may also elicit additional proliferative and recovery effects during injury or                                                                                                                                                                                                                                                                               
sickness. The first of these studies on wound recovery involves the role of GH as a 
neurotropic factor. One treatment that may allow deaf patients to hear is known as a 
cochlear implant. These implantations are only successful if deaf patients have 
normally functioning spiral ganglion neurons. Recent studies indicate that 
neurotropic factors may be able to repair degenerative damage to spiral ganglion 
neurons in patients with hearing loss. GH stimulates neurite growth and neuronal 
branching in other neuron types, so it might also exhibit these effects on spiral 
ganglion neurons. A research group in Frankfurt, Germany attempted to evaluate 
whether GH is a possible treatment to reverse spiral ganglion degeneration. They 
examined the effects of GH on the inner ear spiral ganglia from mice. This 
experiment was conducted in vitro. They observed significant neurite growth in the 
petri dish ganglia which supports that GH could be a possible neuro regenerative 
treatment to enable the use of cochlear implants (Gabrielpillai et al. 638-642).  
Peripheral nerves are able to spontaneously recover without treatment, but 
when regenerated in this manner, they lose a good proportion of their functional 
capabilities. This dilemma has caused scientists to search for treatments that 
improve nerve regeneration. A research group from the University of Santiago de 
Compostela attempted to evaluate if GH treatment could be the solution physicians 
have been searching for. A transection was performed on the left sciatic nerve of 
studied adult rats. Transected rats were then either treated with GH or saline for a 
period of 8 weeks. GH treated rats were observed to have more responsive axons 
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and more Schwann cells than the saline treated rats. GH treated rats also performed 
better in treadmill tests than did the saline rats (Devesa et al. 385-91). These results 
support that GH could be a possible treatment to induce peripheral nerve 
regeneration. 
Growth hormone may also be able to accelerate and improve wound healing 
in other types of tissue. Some believe that this effect may be caused by GH 
stimulating the wound area to produce more IGF-1. One study published in the 
journal Wounds discussed the effects of GH on wounded pigs. Pigs were given 
either GH (2.5 IU/L applied to topically to the wound) or saline every other day. 
Eleven applications (i.e. for each pig) of the saline or GH were given overall. Weekly 
biopsies were used to evaluate the rate of wound healing in the pigs. Wounds were 
observed to consistently heal faster in the GH-treated group than the control group 
(p < 0.05). GH-treated pigs also had more collagen 1 and IGF-1 produced than 
saline pigs (Kim et al. 159-161). These results support that GH may expedite wound 
healing. Further research is necessary to determine if GH has similar effects in 
humans though. 
GH does regulate bone elongation. Could these effects and the above wound 
healing data indicate that GH treatment might accelerate bone repair as well? A 
study done in 2007 investigated this very subject. Researchers measured how GH 
treatment affected the duration of time required to repair different types of tibia 
fractures. Four hundred and six human patients (93 females and 313 males with 
ages ranging between 18 and 34) were examined in this double-blind study. 
Subjects had either an open or closed tibial fracture. Each patient was randomly 
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assigned to either receive saline or growth hormone (15, 30, or 60 mg/kg daily 
depending on the subgroup). Treatment ceased after full recovery was observed or 
after 16 weeks of continuous treatment. Patients were observed every 4 weeks until 
24 weeks had passed. Post assessment was also conducted 9 months and 12 
months after the treatment began. There was no significant difference in open 
fracture healing time between the control and the GH treated patients. GH treatment 
for closed fracture patients yielded drastically different results. The subgroup treated 
with 60 mg/kg of GH daily had an average 26% decrease in recovery time over the 
control group (Raschke et al. 343-349). Why there is such a stark contrast for 
effectiveness of GH between both fracture types is still unknown. Regardless, the 
data does support that GH treatment could reduce healing time for closed fractures.  
The survey conducted for this thesis also asked GHD patients to describe 
their wound healing rate. “What is the average duration of time that you have spent 
out of work or school due to an injury?” The available answer choices for this 
question were: I typically stay out of work/school for more than one month; I typically 
stay out of work/school for about one month; I typically stay out of work/school for 
about 3 weeks; I typically stay out of work/school for about 2 weeks; I typically stay 
out of work/school for about 10-13 days; I typically stay out of work/school for about 
7-9 days; I typically stay out of work/school for about 4-6 days; and I typically stay 
out of work/school for about 1-3 days. The prevalence of responses chosen for this 
question can be found in Figure 37 (Appendix C). ANOVA analysis (Figure 17) 
revealed that variance between selected answers was statistically significant (p < 
0.0001). 
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Figure 17. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 18 data. M+: stayed out for more 
than a month, M: stayed out for a month; 3W: stayed out for 3 weeks; 2W: stayed 
out for 2 weeks; 10-13D: stayed out for 10-13 days; 7-9D: stayed out for 7-9 days; 4-
6D: stayed out for 4-6 days; 1-3D: stayed out for 1-3 days. 
 Fifty five percent of those surveyed said that they stayed out for 1 to 3 days. 
This result could support that GH boosts wound regeneration rates, but more 
research is needed to truly determine a cause and effect. This data might have more 
validity if it were to be compared with that of a control group which was asked the 
same question.  
Immune System: 
GH’s effects on the immune system will now be discussed. A 2009 study 
reviewed how GH and Ghrelin affect the immune system. These hormones have 
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been observed to interact with T lymphocytes, B lymphocytes, monocytes and 
neutrophils. Each of these cells also contain GHRs and Growth Hormone 
Secretagogue Receptors (GHS-Rs). Ghrelin appears to cause a signal cascade 
when it interacts with GHS-R. This may indicate that Ghrelin plays an important role 
in the regulation of the hypothalamic-pituitary axis. The conservative nature of cells 
signifies that all molecules produced by a cell are also used by the cell in some way. 
Thus, the sheer fact that these immune cells possess GHRs and GHS-Rs 
corroborates the claim that Ghrelin and GH have a role in regulating the immune 
system. This study reports that GH is responsible for “enhancing thymopoiesis and T 
cell development, modulating cytokine production, enhancing B cell development 
and antibody production, priming neutrophils and monocytes for superoxide anion 
secretion, enhancing neutrophil adhesion and monocyte migration and anti-apoptotic 
action” (Hattori 347). Ghrelin plays a role in the reduction of inflammation, the 
regulation of thymopoiesis, the reduction of sepsis, and the regulation of 
phagocytosis. It remains to be known whether the effects of Ghrelin are elicited by 
GH or if the GH effects are elicited by IGF-1.  
Results from other studies further support that GH affects the innate immune 
system. A 2019 cancer cachexia study in the Journal PloS One observed that GH 
activates and stimulates the proliferation of NK cells in cancer induced rats (Wei et 
al. 6-7). Another study done in 2013 found that in vivo GH treatment of peritoneal 
macrophages had caused these cells to be more phagocytic than the control (Reis 
et al. 1). A 2004 review in the Journal of Pediatric Endocrine Reviews compiled a list 
of other innate immune system effects. It mentions that GH was observed to 
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stimulate the proliferation and differentiation of myeloid progenitor cells, that GH 
stimulated monocyte chemotaxis and migration, and also caused monocytes; 
macrophages; and neutrophils to increase production of phagocytic chemicals (i.e. 
superoxide anions and hydrogen peroxide for monocytes) (Meazza et al. 5-6).  
These studies support that GH could affect leukocyte regulation. They also 
suggest that HGH could be used to boost immune function. There were also 
questions in the survey conducted for this thesis that asked GHD patients to 
describe how GH therapy effected their immune system. “Has your rate of 
contracting an illness changed since you began GH therapy?” The available answer 
choices were: yes, I have noticed that I have contracted 4 or more illnesses on 
average than I did before I began GH treatment; yes, I have noticed that I have 
contracted 2 to 3 more illnesses on average than I did before I began GH treatment; 
no, I have noticed no change in my rate of contracting illnesses; yes, I have noticed 
that I catch 2 to 3 fewer illnesses on average that I did before I began GH treatment; 
and yes, I have noticed a major change in my health to such a degree that I now 
typically only contract 1 to 2 illnesses a year. This question is designed to measure 
the strength of the innate immune system within the subjects. Contracting fewer 
illnesses would indicate that the physical barriers and innate immune system 
leukocytes are strong enough to prevent more pathogens from multiplying to the 
degree which would cause the subject to develop symptoms. GH seems to boost the 
protective function of the skin and stimulate innate immune cells such as nk cells, so 
it is possible that GH could enhance the innate immune system and reduce the 
overall number of contracted illnesses. The prevalence of responses chosen for this 
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question can be found in Figure 38 (Appendix C). ANOVA analysis (Figure 18) 
revealed that variance between selected answers was statistically significant (p < 
0.0001). 
  
Figure 18. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 19 data. 4+: additional 4 or more 
contracted illnesses per year; 2-3+: additional 2 to 3 more contracted illnesses per 
year; NC: no change; 2-3-: decrease of 2 to 3 contracted illnesses per year; 1-2Y: 1 
to 2 contracted illnesses per year. 
 Fifty seven percent of those surveyed report that they noticed no change. 
Fifteen percent noticed they had contracted 2-3 fewer illnesses. Another 15% 
reported that GH therapy vastly improved their innate immune function to a degree 
where they now only get sick once or twice a year. The high prevalence of no 
noticeable change may be because individuals do not often think of how many 
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illnesses they contract in a year, but this is only a hypothesis. These results support 
that GH could improve inmate immune system function in some GHD patients.   
“Has the duration of an illness changed since you began GH therapy?” The 
answer choices for this question were: yes, I noticed that a sickness duration is on 
average a week or more longer than it would have been before I began GH 
treatment; yes, I noticed that a sickness duration is on average 4-6 days longer than 
it would have been before I began GH treatment; yes, I noticed that a sickness 
duration is on average 1-3 days longer than it would have been before I began GH 
treatment; I have noticed no change in the average length of sickness following the 
contraction of a pathogen; yes, I noticed that a sickness duration is on average 1-3 
days shorter than it would have been before I began GH treatment; yes, I noticed 
that a sickness duration is on average 4-6 days shorter than it would have been 
before I began GH treatment and yes, I noticed that a sickness duration is on 
average 7-10 days shorter than it would have been before I began GH treatment. 
This question is meant to assess whether GH treatment may cause the adaptive 
immune response (i.e. activation and proliferation of B and T lymphocytes) to occur 
at an earlier point than when the response occurred while these patients did not 
receive GH treatment. Said alteration of response time would shorten the duration of 
sickness in the patients. Thus, the overall duration is gauged to assess adaptive 
immune response time. The prevalence of responses chosen for this question can 
be found in Figure 39 (Appendix C). ANOVA analysis (Figure 19) revealed that 
variance between selected answers was statistically significant (p < 0.0001). 
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Figure 19. ANOVA results, response choice mean, and standard deviation for 
each response group from survey question 20 data. 7+: 7 or more day increase 
in sickness duration; 4-6+: 4 to 6 day increase in sickness duration; 1-3+: 1 to 3 day 
increase in sickness duration; NC: no change; 1-3-: 1 to 3 day decrease in sickness 
duration; 4-6-: 4 to 6 day decrease in sickness duration; 7-: 7 or more day decrease 
in sickness duration. 
 Sixty two percent of those surveyed report no noticeable change. Nearly 17% 
of those surveyed said that their average sickness duration has decreased by 1 to 3 
days. These results support that GH therapy could accelerate adaptive immune 
response in some GHD patients. 
 Further Interpretation of Miscellaneous Findings:  
There is evidence to support that GH may regulate cardiac, integumentary, 
thermoregulation, healing, and immune system functions. Survey results on cardiac 
function do not support that GH effects cardiac function, but more objective studies 
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estimate that GHD patients are at a higher risk of having a heart attack. Survey 
results also support that GH treatment could improve wound healing and immune 
function in GHD patients. Results of literary analyses support that GH might be a 
possible treatment to improve wound healing and boost immune system function in 
normal patients. GHD patients could also have integumentary ailments, but findings 
oppose that GH therapy can attenuate these side effects. Survey results also 
support that GH therapy does not improve thermoregulation. GH has been shown to 
increase while normal individuals are exercising. GHD patients only receive GH 
once in the evening. These results suggest that GH therapy may need to be altered. 
It is hypothesized that a GH pump similar to insulin pumps could attenuate these 
currently unaltered integumentary and thermoregulation impairments because it 
would mimic the natural pulsatile and physical state dependent secretions of GH in 
normal patients. More research is needed to support this hypothesis. Regardless, 
results from the survey and literary analysis of recent findings support that GH could 
be necessary to maintain healthy cardiac, integumentary, recovery, and immune 
system functions.  
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Chapter 4: Conclusion  
There is evidence to support that GH regulates many more functions than 
bone elongation. This thesis has discussed both the analysis of its survey and recent 
study results that evaluate these additional roles. Previously mentioned data 
supports that GH could regulate energy, metabolism, physical capacity, mental 
health, sleep, cognition, cardiovascular health, the integumentary system, 
thermoregulation, wound regeneration, and immune system function. Findings 
suggest that GH is much more important to the body than was once thought.  
Recent findings and analysis of the survey conducted for this thesis support 
that GH treatment could be necessary for GHD patients to live a long and healthy 
life. Without GH these patients could have mental health conditions, low energy 
levels, obesity, impaired immune system function, impaired cardiovascular system 
function, impaired exercise ability, cognitive impairment, dysfunctional sleep, and 
heat sensitivity. Each of these factors would greatly diminish the quality of the 
patient’s life and could shorten the length of their life. There is strong evidence to 
support that GH therapy is a necessity for GHD patients of any age. These findings 
also suggest that clinicians may need to rethink how they treat GHD patients. One 
dose a day may not be enough to attenuate all of the aforementioned side effects. In 
the future, patients might take small dosages of GH when they go to bed, when they 
are fasting, and when they intend to exercise for a long period. GH is not only 
secreted to increase bone elongation, so the cessation of bone elongation does not 
support that GH treatment should cease in adult GHD patients.  
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The discovery of the effects of GH might also improve the lives of normal 
individuals. GH has been observed to improve immune system function in rats with 
cancer, to improve wound healing in pigs, to improve some types of bone repair in 
humans, to improve cognitive function in a patient with a severe traumatic brain 
injury, and to minimize stroke damage in mice. These results support that GH could 
be a possible treatment to boost immune system function, accelerate healing, and 
repair damage that current medicines cannot treat. GH may be used as a treatment 
for these impairments in the coming decade. Though clinical trials of larger samples 
will truly determine if GH is a safe treatment for the aforementioned conditions.  
 It should now be apparent that growth hormone affects much more than 
growth. What should be researched next is how GH treatment can improve the lives 
of individuals without GHD. 
Limitations: 
There are limitations of the survey conducted for this thesis. The survey had a 
low number (86) of respondents, so results should not be used as proof of the 
effects of GH on all individuals with GHD. The sample of subjects includes mostly 
Caucasian women. Results thus do not properly represent all GHD patients. Patients 
were asked to report how they felt about their symptoms. These feelings may not 
translate into objective results if tested further. Patients could have lied. It is also 
possible that the cost of GH may have incentivized the patients to feel that GH has 
had a positive effect on their symptoms.  
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Appendix A: 
 
Figure 20. Prevalence of responses chosen for survey question 1. 
 
Figure 21. Prevalence of responses chosen for survey question 2. 
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Figure 22. Prevalence of responses chosen for survey question 3. 
 
 
 
 
Figure 23. Prevalence of responses chosen for survey question 4. 
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Figure 24. Prevalence of responses chosen for survey question 5. 
 
 
 
Figure 25. Prevalence of responses chosen for survey question 6. 
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Figure 26. Prevalence of responses chosen for survey question 7. 
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Appendix B: 
 
Figure 27. Prevalence of responses chosen for survey question 8. 
 
Figure 28. Prevalence of responses chosen for survey question 9. 
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Figure 29. Prevalence of responses chosen for survey question 10. 
 
 
 
Figure 30. Prevalence of responses chosen for survey question 11. 
Hutchins 77 
 
 
Figure 31. Prevalence of responses chosen for survey question 12. 
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Appendix C: 
 
Figure 32. Prevalence of responses chosen for survey question 13. 
 
 
 
Figure 33. Prevalence of responses chosen for survey question 14. 
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Figure 34. Prevalence of responses chosen for survey question 15. 
 
 
 
Figure 35. Prevalence of responses chosen for survey question 16. 
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Figure 36. Prevalence of responses chosen for survey question 17. 
 
 
 
Figure 37. Prevalence of responses chosen for survey question 18. 
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Figure 38. Prevalence of responses chosen for survey question 19. 
 
 
 
Figure 39. Prevalence of responses chosen for survey question 20. 
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